Related Experiment Video
Updated: Jul 9, 2026

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
Published on: June 2, 2015
Cryoplasty therapy for limb salvage in patients with critical limb ischemia
Tony Das1, Thomas McNamara, Bruce Gray
1Cardiology & Interventional Vascular Associates, Presbyterian Heart Institute, Dallas, TX 75231, USA. Tdas@civadallas.com
Insights
Cryoplasty therapy effectively treats below-knee occlusive disease in critical limb ischemia (CLI) patients, demonstrating high technical success and limb salvage rates at six months.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Endovascular Therapy
Background:
- Critical limb ischemia (CLI) poses significant risks, including amputation.
- Below-knee occlusive disease is a challenging manifestation of CLI.
- Novel endovascular techniques are needed to improve limb salvage rates.
Purpose of the Study:
- To evaluate the 6-month outcomes of cryoplasty (cold balloon angioplasty).
- To assess cryoplasty's safety and efficacy in treating below-knee occlusive disease in CLI patients.
- To determine limb salvage and amputation-free survival rates post-cryoplasty.
Main Methods:
- Prospective multicenter study (Below-the-Knee Chill Study) involving 108 CLI patients.
- 111 limbs treated with cryoplasty for below-knee occlusive disease.
- Primary endpoints: acute technical success and absence of major amputation at 180 days.
Main Results:
- Acute technical success achieved in 97.3% of treated limbs.
- Freedom from major amputation at 180 days was 93.4%.
- Amputation-free survival was 89.3% at 180 days, with lower rates in diabetics.
Conclusions:
- Cryoplasty is a safe and effective treatment for infrapopliteal disease in CLI patients.
- Cryoplasty offers excellent acute outcomes and high limb salvage rates.
- Cryoplasty is a viable primary treatment option for CLI due to below-knee disease.
Purpose:
To report the 6-month outcomes from a prospective multicenter study investigating the use of cryoplasty (cold balloon angioplasty) to treat below-knee occlusive disease in patients with critical limb ischemia (CLI).
Methods:
Between August 2004 and October 2005, 108 patients (77 men; mean age 73+/-12 years, range 41-101) with CLI involving 111 limbs were enrolled in a prospective multicenter trial (Below-the-Knee Chill Study), which was conducted at 16 institutions. The primary study endpoints were acute technical success, defined as the ability to achieve < or =50% residual stenosis and continuous inline flow to the foot, and absence of major (above or below-knee) amputation of the target limb 180 days post procedure.
Results:
Acute technical success was achieved in 108 (97.3%) of the 111 limbs treated, with only 1 (0.9%) clinically significant dissection (> or =type C) and 2 residual stenoses >50%. During the 180-day follow-up, 15 (13.9%) of the initial 108 patients either withdrew or were lost to follow-up. Five (4.6%) deaths occurred, leaving 88 (81.5%) patients with 91 (82.0%) treated limbs available for 180-day assessment. The rate of freedom from major amputation at 180 days was 93.4%. Amputation-free survival was 89.3% at 180 days (5 deaths, 6 major amputations). Stratifying data by diabetics (n=71) versus non-diabetics (n=34), the 180-day death and amputation rates were 4.9% and 10.0%, respectively, for diabetics versus 6.7% and 0.0%, respectively, for non-diabetics.
Conclusion:
Cryoplasty therapy is a safe and effective method of treating infrapopliteal disease, providing excellent acute outcomes and a high rate of limb salvage in patients with CLI. Study outcomes support the use of cryoplasty therapy as a primary treatment option for patients with CLI secondary to below- knee disease.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025